Drug intelligence / Profile preview

IMC003 (Immunofoco)

Development stage: Preclinical
Lead developer: Immunofoco
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

IMC003 is an autologous CAR-T cell therapy being developed by Suzhou Immunofoco Biotechnology for the treatment of solid tumors, specifically digestive system neoplasms. The therapy utilizes the proprietary Peri Cruiser® technology platform, which is designed to reduce on-target off-tumor toxicity, a common safety concern in CAR-T therapies for solid tumors. This technology aims to minimize adverse effects on normal tissues while maintaining treatment efficacy. As of current reports, IMC003 is in the preclinical stage of development, and its specific antigen target has not been publicly disclosed.

Targets

EPCAM (Epithelial cell adhesion molecule)

Beyond the preview

Go deeper on IMC003 (Immunofoco).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMC003 (Immunofoco).

Explore the full profile